| Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer MA Franzoi, E Agostinetto, M Perachino, L Del Mastro, E de Azambuja, ... The Lancet Oncology 22 (7), e303-e313, 2021 | 169 | 2021 |
| Leptomeningeal carcinomatosis in patients with breast cancer MA Franzoi, GN Hortobagyi Critical reviews in oncology/hematology 135, 85-94, 2019 | 132 | 2019 |
| Pregnancy after breast cancer: a systematic review and meta-analysis M Lambertini, E Blondeaux, M Bruzzone, M Perachino, RA Anderson, ... Journal of Clinical Oncology 39 (29), 3293-3305, 2021 | 115 | 2021 |
| Immunotherapy for early breast cancer: too soon, too superficial, or just right? MA Franzoi, E Romano, M Piccart Annals of oncology 32 (3), 323-336, 2021 | 108 | 2021 |
| Systemic therapy for advanced human epidermal growth factor receptor 2–positive breast cancer: ASCO guideline update SH Giordano, MAB Franzoi, S Temin, CK Anders, S Chandarlapaty, ... Journal of Clinical Oncology 40 (23), 2612-2635, 2022 | 101 | 2022 |
| Advanced Stage at Diagnosis and Worse Clinicopathologic Features in Young Women with Breast Cancer in Brazil: A Subanalysis of the AMAZONA III Study (GBECAM 0115) Journal of Global Oncology 5 (november 2019), 1-10, 2019 | 55 | 2019 |
| Management of advanced human epidermal growth factor receptor 2–positive breast cancer and brain metastases: ASCO guideline update N Ramakrishna, CK Anders, NU Lin, A Morikawa, S Temin, ... Journal of Clinical Oncology 40 (23), 2636-2655, 2022 | 53 | 2022 |
| Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis F Poggio, L Del Mastro, M Bruzzone, M Ceppi, MG Razeti, P Fregatti, ... Breast Cancer Research and Treatment, 1-7, 2022 | 51 | 2022 |
| Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials-how to explain different results? MA Franzoi, E de Azambuja ESMO open 5 (6), 2020 | 47 | 2020 |
| Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification D Trapani, MA Franzoi, HJ Burstein, LA Carey, S Delaloge, N Harbeck, ... Annals of Oncology 33 (7), 702-712, 2022 | 32 | 2022 |
| Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors MA Franzoi, C Vandeputte, D Eiger, R Caparica, M Brandão, ... Breast cancer research and treatment 181, 199-209, 2020 | 28 | 2020 |
| Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy MA Franzoi, D Eiger, L Ameye, N Ponde, R Caparica, C De Angelis, ... JNCI: Journal of the National Cancer Institute 113 (4), 462-470, 2021 | 27 | 2021 |
| Differences in breast cancer stage at diagnosis by ethnicity, insurance status, and family income in young women in the USA MA Franzoi, G Schwartsmann, SJ de Azevedo, G Geib, F Zaffaroni, ... Journal of racial and ethnic health disparities 6, 909-916, 2019 | 26 | 2019 |
| DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity OV Neto, S Raymundo, MA Franzoi, A do Carmo Artmann, M Tegner, ... Clinical Biochemistry 56, 18-25, 2018 | 24 | 2018 |
| Impact of HIV infection on baseline characteristics and survival of women with breast cancer M Brandão, M Bruzzone, MA Franzoi, C De Angelis, D Eiger, R Caparica, ... Aids 35 (4), 605-618, 2021 | 23 | 2021 |
| Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial MGDEA Serena Di Cosimo, Luca Porcu, Dominique Agbor-tarh, Saverio Cinieri ... Breast Cancer Research 22 (115), 1-7, 2020 | 21 | 2020 |
| Determination of docetaxel in dried blood spots by LC–MS/MS: method development, validation and clinical application S Raymundo, VV Muller, NB Andriguetti, M Tegner, AC Artmann, ... Journal of Pharmaceutical and Biomedical Analysis 157, 84-91, 2018 | 21 | 2018 |
| Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials D Eiger, MA Franzoi, N Pondé, M Brandão, C De Angelis, MS Nogueira, ... ESMO open 5 (1), e000659, 2020 | 18 | 2020 |
| Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis R Caparica, M Bruzzone, E Agostinetto, MA Franzoi, M Ceppi, ... The Breast 59, 183-192, 2021 | 16 | 2021 |
| Benefícios da hipodermóclise na clínica paliativa de pacientes com câncer: relato de caso G Pontalti, C de Oliveira Riboldi, RS Gioda, IC Echer, MA Franzoi, ... Revista Brasileira de Cancerologia 62 (3), 247-252, 2016 | 16 | 2016 |
